Vaccine engagement of innate immunity via ligands to TLR2 [74] or TLR4 [75,76] or presentation via virus-like particles [77] elicited robust, protective immunity in the absence of post-infection inflammatory responses including pulmonary eosinophilia. The gene discussed is TLR4; the disease is infection.